So far, studies have been published on survival of the various BTs from clinical practice records in patients diagnosed with psoriasis, and longer survival has been found with the IL-12 and IL-23 inhibitor drug (anti-IL-12/23, UTK) compared to anti-TNF drugs [19,20,21,22]. This evidence concerns the gene TNF and psoriasis.